QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte(TM) (synthetic hypericin). The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and commercialization activities for its photodynamic therapy. President and CEO Christopher J. Schaber, PhD, said the addition of new key opinion leaders reinforces the program’s clinical depth and the company’s commitment to bringing HyBryte to CTCL patients worldwide. To view the full press release, visit https://ibn.fm/9LzBI…